medRxiv preprint doi: https://doi.org/10.1101/2022.01.12.22268892; this version posted March 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Analysis of cell-specific peripheral blood biomarkers in severe allergic asthma identifies innate immune dysfunction

Ben Nicholas[1], Jane Guo[2], Hyun-Hee Lee[2], Alistair Bailey[3], Rene de Waal Malefyt[4], Milenko Cicmil[2] and Ratko Djukanovic[1]

[1] Division of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Hampshire, United Kingdom

[2] Oncology & Immunology Discovery, Merck Research Laboratories, Boston, MA, United States of America

[3] Cancer Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Hampshire, United Kingdom

[4] Merck Research Laboratories, Palo Alto, California, United States of America

ORCIDs:

Ben Nicholas: 0000-0003-1467-9643

Jane Guo:

Hyun-Hee Lee:

Alistair Bailey: 0000-0003-0023-8679

Rene de Waal Malefyt: 0000-0002-2663-383X

Milenko Cicmil:

Ratko Djukanovic: 0000-0001-6039-5612

Running title: Peripheral blood biomarkers of severe asthma

Keywords: Asthma, biomarkers, allergy, peripheral, transcriptomic

Correspondence to:

Dr Ben Nicholas

Centre for Proteomic Research
B85, Life Sciences Building
University of Southampton
University Road
Highfield
Southampton, Hants.
SO17 1BJ

Tel No: +44(0)2380 59 5503

Email: bln1@soton.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.12.22268892; this version posted March 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

Asthma is a disease of complex origin and multiple pathologies. There are currently very few biomarkers of proven utility in its diagnosis, management or response to treatment. Recent studies have identified multiple asthma phenotypes following biofluid analysis; however, such findings may be driven by the well-characterised alterations in immune cell populations in asthma. We present a study designed to identify cell type-specific gene signatures of severe allergic asthma in peripheral blood samples. Using transcriptomic profiling of four magnetically purified peripheral blood cell types, we identify significant gene expression changes in monocytes and NK cells but not T lymphocytes in severe asthmatics. Pathway analysis indicates dysfunction of immune cell regulation and bacterial suppression in the NK cells. These gene expression changes may be useful on their own as prognostic peripheral blood cell markers of severe asthma, but also may indicate novel cell pathways for therapeutic intervention.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.12.22268892; this version posted March 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Asthma is a common chronic airways disease with complex aetiology, having no single causative genetic trigger, and with multiple factors appearing to contribute to disease pathogenesis [1]. Thus, asthma can manifest in numerous different pathologies related to severity and the degree of allergy or response to therapeutic intervention. Currently, the principal clinical biomarkers for initial diagnosis and staging of disease severity include lung function and hyper-responsiveness tests. Sometimes fractional exhaled nitric oxide (FeNO) is used as a surrogate for direct measurement of eosinophils. Improvement of clinical symptoms following therapeutic intervention and assessment of atopy and a history of wheeze are also useful.

Monitoring of the disease is generally through symptom assessment and therapeutic dose requirements combined with periodic lung function tests. Novel approaches, such as immunotherapy, have identified the utility of additional biomarkers such as IgE or sputum inflammatory cell counts as inclusion criteria; however, in clinical practice, often the principal read-outs remain the generalised clinical ones. No single test provides definitive evidence of asthma, its severity or therapeutic efficacy of drugs.

Recent reports identified multiple disease phenotypes using unbiased clustering of genomic and proteomic data from airway samples[2]. Likewise, mRNA signatures of severe asthma have been identified in whole blood [3]. The importance of such studies may be confounded by known changes in inflammatory cell profiles in asthma, thus, missing changes in blood cell-subtypes by defining the phenotypic clusters of subjects based on inflammatory cell predominance in biofluids.

Our approach was to gene expression markers of cell type and asthma in four peripheral blood cell populations. We recruited 11 severe allergic asthmatics on step 4 of BTS/Sign management, and 10 healthy control subjects (see Table 1 for a summary of patient characteristics). Participants signed written informed consent.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.12.22268892; this version posted March 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. Clinical characteristics for the healthy and moderate/severe allergic asthmatic cohorts.

	Healthy controls	Severe allergic asthmatics	p value
N	10	11	-
Gender (M/F)	3/7	3/8	-
Age	42.5 (31-53)	43 (31-50)	0.87
Atopy (yes)	0	11	-
Total blood IgE	16.45 (10.7-27.8)	163.9 (71.4-315.0)	0.0003***
Blood lymphocytes	1.9 (1.75-2.125)	1.9 (1.7-2.1)	0.345
Blood eosinophils (%)	0.1 (0.1-0.2)	0.2 (0.1-0.3)	0.212
Pre FEV1	3.11 (2.89-4.13)	2.58 (2.15-3.49)	0.043*
Pre FEV1 % predicted	111.4 (105.3-117.1)	100 (77.2-102.4)	0.016*
Post FEV1	3.19 (3.04-4.19)	3.00 (2.37-3.66)	0.067
Post FEV1 % predicted	114.1 (107.7-119.4)	100.6 (86.2-114.7)	0.055
Sputum eosinophils (%)	0	1.69 (0-3.68)	0.046*
Sputum neutrophils (%)	11.36 (7.1-15.7)	64.46 (21.9-74.2)	0.006**
PBMC CD4+ (% of CD3+)	65.9 (53.5-71.2)	70.3 (58.5-78.5)	0.251
PBMC CD8+ (% of CD3+)	26.7 (18.6-33.0)	23.9 (16.8-26.5)	0.340
PBMC monocytes (% of CD45+)	11.7 (10.2-16.4)	12.8 (8.7-14.0)	0.878
PBMC NK cells (% of Cd45+)	11.1 (8.8-19.5)	10.6 (7.4-11.7)	0.314

Mann Whitney tests, *p<0.05, **p<0.01, ***p<0.001 Data shown are medians (+/- interquartile range)

Fresh blood was drawn and PBMCs were isolated from buffy coats. Flow cytometry determined no significant differences in the relative proportions of four immune cell populations, monocytes, NK cells, CD4+ and CD8+ T cells in the peripheral blood of healthy and severe asthmatic subjects (Table 1).

Four cell populations were sequentially enriched from 4 x 10^7 PBMCs from each subject using magnetic beads conjugated to monoclonal antibodies targeting

medRxiv preprint doi: https://doi.org/10.1101/2022.01.12.22268892; this version posted March 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

different cell surface markers, namely CD14 (monocytes), CD56 (NK/NK-T cells), CD8 (CD8+ T cells), and CD4 (CD4+ T cells) in that order. This yielded populations highly enriched (>99%) for each selective marker.

Quantification of gene expression used isolated RNA from the four enriched cell populations, analysed by a 770 gene nCounter pan cancer immune profiling array (NanoString Technologies).

Unbiased principal component analysis (PCA) of the purified cell gene expression profiles robustly separated the four target cell populations (Figure 1A). The genes primarily driving cluster separation of each cell type, and as such indicative of cell-specific biomarkers, confirm the purity of our immune blood cell populations and add to the canon of knowledge on markers of these cell types (see online data supplement for cell-specific gene lists: https://doi.org/10.6084/m9.figshare.19329068).

For example, a major component of the monocyte cluster was CD14, which was to be expected since it was the target isolation molecule, but also includes 425 other genes contributing to this cluster, inclusive of the well-characterised monocyte-specific proteins such as CD68, CD163, L-selectin and S100A12.

T cells exhibit a well-defined cluster, however a small degree of overlap between the CD4+ and CD8 + T cell clusters, reflects the phenotypic similarity between these two cell types. Their combined cluster includes CD3 and CD8.

Similarly, our top-ranked genes contributing to the NK cell cluster are well-known phenotypic markers of NK cells, inclusive of KLRD1, NCAM-1 and EOMES. Clusters were driven primarily by cell type. We found little evidence of segregation between health and asthma in these cell populations.

We then identified differentially expressed genes (DEGs) in asthma, adjusting for multiple tests for each cell type as appropriate. Volcano plots (Figure 1B) indicate two genes upregulated in asthmatic monocytes compared to healthy controls (IGF2R and C3AR1). IGF2R is upregulated in monocytes during differentiation into macrophages [4] but changes in IGF2R expression by monocytes in asthma have not previously been observed. C3AR1 has been previously identified as a susceptibility

medRxiv preprint doi: https://doi.org/10.1101/2022.01.12.22268892; this version posted March 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

gene for bronchial asthma [5]. To our knowledge, no previous studies have identified elevation of the C3AR1 in monocytes of severe asthmatics.

We found six upregulated (LILRA5, LILRB2 and SLC11A1, PDGFRB, LYN, CD97) and eight downregulated (LTB, RORC, GZMK, DPP4, RPS6, FLT3LG, DOCK9 and CD28) genes in CD56+ cells from asthmatics.

Several of these upregulated genes are associated with immune cell regulation. For example, the leukocyte immunoglobulin-like immunoregulatory checkpoint receptors LILRA5 and LILRB2 have both positive and negative regulatory properties, whereas LYN-dependent signalling is primarily a negative regulator of innate and adaptive immune responses[6]. Additionally, the PDGF pathway has a well described local airways role in asthma pathogenesis and airway remodelling. Increased systemic levels of PDGF ligands in the serum of asthmatics have been previously observed, however it has remained uncertain whether PDGF is a systemic biomarker of asthma[7]. Our study suggests that PDGF-receptor expression may provide evidence of systemic response to abnormal PDGF expression in asthma.

Another upregulated gene in asthmatic NK cells is involved in pathogen resistance; SLC11A1 plays a role in divalent metal ion transport, promoting anti-microbial pathogen responses. This protein is upregulated in local innate lymphocytic cell subtypes in asthma, augmenting their activation and biasing towards a Th1 rather than Th2 response. Abnormal SLC11A1 expression has previously been identified in asthmatic sputum cells[8], attributed to localised bacterial exposure. Systemic changes in expression of SLC11A1 may reflect the disease severity and the consequent neutrophilic phenotype of our severe asthma cohort. However, the existence of SLC11A1 upregulation in the peripheral is suggestive of widespread systemic innate cell dysfunction.

Conversely, several genes downregulated in CD56+ cells of asthmatics (LTB, RORC, GZMK, DPP4, RPS6, FLT3LG, DOCK9 and CD28), are associated with proinflammatory, functional, cell or activation responses in NK cells. For example, lymphotoxin beta is a pro-inflammatory TNF-α superfamily member, granzyme K is a serine protease and component of cytotoxic granules in NK cells, and CD28 is a co-stimulatory molecule for NK cells. Interestingly, DPP4, which plays a role in NK cell

medRxiv preprint doi: https://doi.org/10.1101/2022.01.12.22268892; this version posted March 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

activation [9] is one of the ligands of IGF2R which is elevated in monocytes and may be suggestive of common systemic pathway alterations in peripheral innate cells.



Figure 1. Differential gene expression analysis in RNA transcripts in severe asthma. (A) PCA analysis of gene counts from all four cell types indicate clusters corresponding to each cell type. **(B)** Volcano plots indicating genes significantly up or down regulated in severe asthma in each cell type (p-adjusted < 0.05). **(C)** Summary of GO terms associated with differential gene expression in NK cells in asthma.

Pathway analysis using the differentially expressed genes in the NK cell-enriched population (Figure 1C) confirmed that severe allergic asthma was associated with upregulation of pathways involved in metabolism, divalent metal ion transport, immune response inhibition, and immune regulation/tolerance, and with downregulation of T cell activation and immune system development.

Overall, these data suggest that an increased tolerogenic environment accompanies severe asthma, and NK cell dysfunctions that would impair the adaptive immune

medRxiv preprint doi: https://doi.org/10.1101/2022.01.12.22268892; this version posted March 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

response were observed that could reflect exhaustion or generalised impairment of these cells. In addition, they show enhanced anti-microbial responses in the absence of recent exacerbation. Although NK and NK-like cells have been examined in asthma, no fixed role for them has yet been assigned. Our study suggests that further investigation of these cells is warranted.

Additionally, monocytes in asthma show increases in gene expression associated with differentiation and chemotaxis. Thus, we find innate but not adaptive cell phenotypic changes in peripheral blood cells from severe asthmatics.

Given the increasing interest in innate immunity and its role in antimicrobial responses, these results suggest the value of further study of gene expression changes at times of acute asthma exacerbations.

The findings presented herein may help to identify new therapeutic avenues for severe asthma arising from innate immunity, and also may serve to identify new gene candidates as useful cell type-specific biomarkers.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.12.22268892; this version posted March 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References

1. Holgate, S.T., *et al.* Asthma. *Nat Rev Dis Primers* 1, 15025 (2015).

2. Takahashi, K., *et al.* Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis. *Eur Respir J* 51(2018).

3. Bigler, J., *et al.* A Severe Asthma Disease Signature from Gene Expression Profiling of Peripheral Blood from U-BIOPRED Cohorts. *Am J Respir Crit Care Med* 195, 1311-1320 (2017).

4. Ohradanova-Repic, A., *et al.* The mannose 6-phosphate/insulin-like growth factor 2 receptor mediates plasminogen-induced efferocytosis. *J Leukoc Biol* 105, 519-530 (2019).

5. Hasegawa, K., *et al.* Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. *Hum Genet* 115, 295-301 (2004).

6. Brown D, Trowsdale J, Allen R. The LILR Family: Modulators of Innate and Adaptive Immune Pathways in Health and Disease. *Tissue Antigens* 64, 215–25 (2004)

7. Kardas,G., et al, Role of platelet-derived growth factor (PDGF) in asthma as an immunoregulatory factor mediating airway remodelling and possible pharmacological target. Front. Pharmacol. 11, 1-8 (2020)

8. Hedges JF, et al, Solute carrier 571 11A1 is expressed by innate lymphocytes and augments their activation. J. Immunol. 190, 4263-4273 (2013)

9. Klemann, C., Wagner, L., Stephan, M. & von Horsten, S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system. *Clin Exp Immunol* 185, 1-21 (2016).